Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INTUITIVE SURGICAL, INC.

(ISRG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Intuitive Surgical : Prior Art Showing An Invention To Be "At Least Possible" Found Sufficient To Invalidate Surgical Device Patent

08/30/2021 | 10:10am EDT

On August 23rd, the Federal Circuit upheld in part and reversed in part a decision from the Patent Trial and Appeal Board's (PTAB or Board) concerning Ethicon's patent on a robotic surgical tool, holding that the Board's finding of no motivation to combine is not supported by substantial evidence. In doing so, the court determined the PTAB "went too far" in its holding of non-obviousness by requiring Intuitive to specifically identify a preexisting surgical device performing as many functions as required by the Ethicon patent; it was enough that the prior art established such a device was "at least possible."

Ethicon and Intuitive Surgical are competitors in the surgical technology market. Ethicon owns U.S. Patent No. 8,616,431 directed to a tool mounting device for coupling a surgical tool to a robotic system with four output bodies to control five different motions or functions. Intuitive filed an inter partes review on anticipation and obviousness grounds. With respect to the obviousness grounds, Intuitive Surgical relied on the combination of two earlier patents - the "Tierney Patent" and the "Whitman Patent."

The Tierney Patent disclosed a robotic surgical system where a number of different tool types can be coupled to a robotic manipulator. The device of the Tierney Patent comprises four rotary drive elements that control only four different motions. The Whitman Patent discloses a shifter that allows a single rotary output body to control more than one motion.

Ethicon did not dispute—either before the Board or on appeal—Intuitive's assertion that the prior art teaches each and every limitation of all of the challenged claims. Ethicon's sole argument before the Board was that a person of ordinary skill in the art would not have been motivated to combine the prior art references to arrive at the claimed invention. The Board agreed with Ethicon. The Board recognized that the combination of Whitman and Tierney would be able to perform more than the four functions disclosed in Tierney. However, it was unpersuaded that a person of ordinary skill would have been motivated to combine the references because Intuitive failed to identify a surgical instrument in the prior art that performed more than four functions. As a result, the PTAB determined there would be no need "to obtain a functionality for which there was no use."

The Federal Circuit disagreed, finding, as an initial matter, the Board's determination that Intuitive failed to identify a surgical instrument performing more than four functions was not supported by the evidence; Intuitive had, in fact, cited a third patent (the "Timm Patent") disclosing at least five different functions. However, even without the Timm Patent, the Federal Circuit found Intuitive presented enough evidence that the combination of Whitman and Tierney rendered the challenged claims obvious.

The Federal Circuit found it was enough that the combination of Whitman and Tierney would allow for more than four functions; the prior art disclosed that a device performing more than four functions was "at least possible." In light of this evidence, the Federal Circuit found the PTAB erred in requiring Intuitive to specifically identify a preexisting device that actually performed more than four functions.

This decision underscores that a finding of obviousness may result when a combination of prior art shows the claimed technology to be "at least possible".

Prior Art Showing An Invention To Be "At Least Possible" Found Sufficient To Invalidate Surgical Device Patent

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Ms Anisha Shenai-Khatkhate
Proskauer Rose LLP
Eleven Times Square
(Eighth Avenue & 41st Street)
New York
10036-8299
UNITED STATES
Tel: 2129693000
Fax: 2129692900
E-mail: gpolk@proskauer.com
URL: www.proskauer.com

© Mondaq Ltd, 2021 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

All news about INTUITIVE SURGICAL, INC.
10/26INSIDER SELL : Intuitive Surgical
MT
10/21INTUITIVE SURGICAL : Morgan Stanley Adjusts Price Target on Intuitive Surgical to $325 fro..
MT
10/20INTUITIVE SURGICAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
10/20Tranche Update on Intuitive Surgical, Inc.'s Equity Buyback Plan announced on February ..
CI
10/20INTUITIVE SURGICAL : Wells Fargo Adjusts Intuitive Surgical's Price Target to $381 from $3..
MT
10/20INTUITIVE SURGICAL : UBS Adjusts Price Target on Intuitive Surgical to $352 From $323 on I..
MT
10/20INTUITIVE SURGICAL : Deutsche Bank Adjusts Intuitive Surgical PT to $323 From $306, Mainta..
MT
10/19Intuitive Surgical 3Q Beats Analyst Views
DJ
10/19Intuitive Surgical Names Executives for Strategy and Growth, Global Business Services
DJ
10/19INTUITIVE SURGICAL : Q3 Non-GAAP Earnings, Revenue Rise From Last Year
MT
More news
Analyst Recommendations on INTUITIVE SURGICAL, INC.
More recommendations
Financials (USD)
Sales 2021 5 651 M - -
Net income 2021 1 661 M - -
Net cash 2021 2 911 M - -
P/E ratio 2021 78,3x
Yield 2021 -
Capitalization 125 B 125 B -
EV / Sales 2021 21,5x
EV / Sales 2022 18,6x
Nbr of Employees 8 081
Free-Float 97,1%
Chart INTUITIVE SURGICAL, INC.
Duration : Period :
Intuitive Surgical, Inc. Technical Analysis Chart | ISRG | US46120E6023 | MarketScreener
Technical analysis trends INTUITIVE SURGICAL, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 348,98 $
Average target price 343,24 $
Spread / Average Target -1,65%
EPS Revisions
Managers and Directors
Gary S. Guthart President, Chief Executive Officer & Director
Marshall L. Mohr Chief Financial Officer & Executive Vice President
Calvin Darling Senior Director-Finance & Investor Relations
Craig H. Barratt Chairman
Myriam J. Curet Chief Medical Officer & Executive Vice President
Sector and Competitors